GB001 in Adult Subjects With Moderate to Severe Asthma

NCT ID: NCT03683576

Last Updated: 2021-09-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

481 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-22

Study Completion Date

2020-08-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance therapy in adults with moderate to severe asthma and an eosinophilic phenotype with respect to asthma worsening at the end of 24 weeks of treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Placebo once per day (QD) for 24 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

film-coated oral tablet

GB001 20 mg

GB001 20 mg QD for 24 weeks

Group Type EXPERIMENTAL

GB001

Intervention Type DRUG

film-coated oral tablet

GB001 40 mg

GB001 40 mg QD for 24 weeks

Group Type EXPERIMENTAL

GB001

Intervention Type DRUG

film-coated oral tablet

GB001 60 mg

GB001 60 mg QD for 24 weeks

Group Type EXPERIMENTAL

GB001

Intervention Type DRUG

film-coated oral tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GB001

film-coated oral tablet

Intervention Type DRUG

Placebo

film-coated oral tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A diagnosis of asthma by a physician at least 12 months before Screening Visit.
* Treated with medium or high dose inhaled corticosteroid (ICS) plus additional controller for at least 12 months prior to Screening Visit. Subjects must maintain a stable ICS dose regimen during the 4 weeks prior to the Screening Visit.
* Forced Expiratory Volume in 1 second (FEV1) of ≤ 85% of predicted normal
* Demonstrated reversibility of at least 12% in FEV1
* Evidence of uncontrolled asthma
* Eosinophilic asthma
* No changes in ICS dose and compliant with standard of care asthma therapy during run-in period.

Exclusion Criteria

* Current smokers (any substance)
* Serious co-morbidities
* Fridericia's correction QT factor (QTcF) ≥450 msec (male) or ≥470 msec (female)
* Use of other investigational drugs within 30 days, or within 5 half-lives, whichever is longer, prior to Screening Visit
* Regular use of systemic corticosteroids or immunosuppressive treatments or monoclonal antibodies for asthma
* Pregnant or breastfeeding
Minimum Eligible Age

18 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Research Center of Albama, LLC

Birmingham, Alabama, United States

Site Status

Banner University of Arizona Medical Center

Tucson, Arizona, United States

Site Status

California Allergy and Asthma Medical Group

Los Angeles, California, United States

Site Status

Southern California Institute for Respiratory Diseases, Inc.

Los Angeles, California, United States

Site Status

North Bay Clinical Trials, Inc

Napa, California, United States

Site Status

Allergy, Asthma & Sinus Consultants, Inc

Riverside, California, United States

Site Status

Integrated Research of Inland, Inc.

Riverside, California, United States

Site Status

Allergy & Asthma Medical Group and Research Center, A P.C.

San Diego, California, United States

Site Status

Allergy and Asthma Associates of Santa Clara Valley Research Center

San Jose, California, United States

Site Status

Bensch Clinical Research LLC

Stockton, California, United States

Site Status

Pulmonary Associates

Colorado Springs, Colorado, United States

Site Status

Yale New Haven Hospital

New Haven, Connecticut, United States

Site Status

Central Florida Pulmonary Group, PA

Altamonte Springs, Florida, United States

Site Status

Central Florida Pulmonary Group, PA

Orlando, Florida, United States

Site Status

Emerald Coast Research Associates

Panama City, Florida, United States

Site Status

Allergy and Asthma Diagnostic Treatment Center

Tallahassee, Florida, United States

Site Status

Clinical Research Trials of Florida, Inc.

Tampa, Florida, United States

Site Status

The Emory Clinic

Atlanta, Georgia, United States

Site Status

Atlanta Allergy & Asthma Clinic, PA,

Marietta, Georgia, United States

Site Status

Atlanta Allergy & Asthma Clinic, PA

Stockbridge, Georgia, United States

Site Status

Treasure Valley Medical Research

Boise, Idaho, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

Allergy & Asthma Specialists, PSC

Owensboro, Kentucky, United States

Site Status

John Hopkins Asthma and Allergy Center

Baltimore, Maryland, United States

Site Status

Brigham and Women's Hospital

Boston, Massachusetts, United States

Site Status

University of Michigan Medicine

Ann Arbor, Michigan, United States

Site Status

Clinical Research Institute, Inc.

Minneapolis, Minnesota, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Atlantic Research Center, LLC

Ocean City, New Jersey, United States

Site Status

American Health Research

Charlotte, North Carolina, United States

Site Status

Clinical Research of Charlotte

Charlotte, North Carolina, United States

Site Status

Wake Forest Baptist Health

Winston-Salem, North Carolina, United States

Site Status

Bernstein Clinical Research Center, LLC

Cincinnati, Ohio, United States

Site Status

Cleveland Clinic

Cleveland, Ohio, United States

Site Status

Oklahoma Institute of Allergy & Asthma Clinical Research, LLC

Oklahoma City, Oklahoma, United States

Site Status

Crisor, LLC

Medford, Oregon, United States

Site Status

Allergy and Clinical Immunology Associates

Pittsburgh, Pennsylvania, United States

Site Status

Berks Schuylkill Respiratory Specialists, Ltd.

Wyomissing, Pennsylvania, United States

Site Status

AAPRI Clinical Research Institute

Warwick, Rhode Island, United States

Site Status

Clinical Research of Rock Hill

Rock Hill, South Carolina, United States

Site Status

Corsicana Medical Research, LLC

Corsicana, Texas, United States

Site Status

Western Sky Medical Research

El Paso, Texas, United States

Site Status

Baylor College of Medicine

Houston, Texas, United States

Site Status

Allergy and Asthma Research Center, PA

San Antonio, Texas, United States

Site Status

Pulmonary Research of Abingdon, LLC

Abingdon, Virginia, United States

Site Status

MultiCare Institute for Research & Innovation

Tacoma, Washington, United States

Site Status

University of Wisconsin School of Medicine and Public Health Asthma, Allergy, and Pulmonary Clinical Research

Madison, Wisconsin, United States

Site Status

Ordination Dr. Robert Voves

Feldbach, , Austria

Site Status

SALK University Hospital Salzburg, State Hospital Salzburg

Salzburg, , Austria

Site Status

Medical University of Vienna, Department of Internal Medicine II, Clinical Division of Pulmonolog

Vienna, , Austria

Site Status

UCL Saint-Luc - Pneumology Department

Brussels, , Belgium

Site Status

Pneumocare sprl

Erpent, , Belgium

Site Status

UZ Gent - Department of Respiratory Medicine

Ghent, , Belgium

Site Status

CHU de Charleroi - Site André Vésale

Montigny-le-Tilleul, , Belgium

Site Status

Inspiration Research Limited

Toronto, Ontario, Canada

Site Status

CHUM - Departement de pneumologie

Montreal, Quebec, Canada

Site Status

Allergiste & Immunologue - Clinic/Outpatient Facility

Montreal, Quebec, Canada

Site Status

Centre integre universitaire de sante et de services sociaux du Nord-de-I'lle-de-Montreal - Hopital du Sacre-Coeur de Montreal

Montreal, , Canada

Site Status

Dr. Jamie Del Carpio's Clinic

Montreal, , Canada

Site Status

Inspirational Research Limited

Toronto, , Canada

Site Status

C. I. C Mauricie Inc.

Trois-Rivières, , Canada

Site Status

The Lung Centre, Vancouver General Hospital

Vancouver, , Canada

Site Status

St. Anne's University Hospital Brno, Institute of Clinical Immunology and Allergology

Brno, , Czechia

Site Status

University Hospital Hradec Kralove, Institute of Clinical Immunology and Allergollogy

Hradec Králové, , Czechia

Site Status

MediTrial s.r.o.

Jindřichův Hradec, , Czechia

Site Status

PNEUMO-KV s.r.o.

Karlovy Vary, , Czechia

Site Status

Pulmonary Outpatient Clinic - Dr. Otakar Hokynar

Kralupy nad Vltavou, , Czechia

Site Status

University Hospital Olomouc, Department of Allergology and Clinical Immunology

Olomouc, , Czechia

Site Status

Medicon a.s.

Prague, , Czechia

Site Status

Pulmonary Outpatient Clinic Rokycany s.r.o.

Rokycany, , Czechia

Site Status

Outpatient Allergology and Neurology Clinic Kasmed Ltd.

Tábor, , Czechia

Site Status

La Croix Rousse Hospital

Lyon, , France

Site Status

Nord G&R Laennec Hospital

Nantes, , France

Site Status

Centre Hospitalier Annecy Genevois

Pringy, , France

Site Status

NOUVEL HOPITAL CIVIL - New Civil Hospital

Strasbourg, , France

Site Status

Universitatsklinikum des Saarlandes, Klinik fur Innere Medizin V

Homburg, Saarland, Germany

Site Status

RCMS Dr. Linhoff

Berlin, , Germany

Site Status

Pneumologisches Studienzentrum Margrafenstrasse

Berlin, , Germany

Site Status

Institut fuer Allergie - und Asthmaforschung

Berlin, , Germany

Site Status

Pneumologische Praxis am Schloss

Berlin, , Germany

Site Status

IKF Pneumologie GmbH & Co. KG

Frankfurt am Main, , Germany

Site Status

Pneumologicum im Suedstadtforum

Hanover, , Germany

Site Status

Schmid

Koblenz, , Germany

Site Status

BAG Prof. Hoheisel/Dr. A. Bonitz

Leipzig, , Germany

Site Status

Pneumologische Praxis PD Dr. med.

Leipzig, , Germany

Site Status

KLB Gesundheitsforschung Luebeck GmbH

Lübeck, , Germany

Site Status

Universitätsmedizin der Johannes Gutenberg-Universität Mainz - Hospital

Mainz, , Germany

Site Status

Centrum Medycyny Oddechowej Mroz sp. j.

Bialystok, , Poland

Site Status

Malopolskie Centrum Alergologii

Krakow, , Poland

Site Status

Niepubliczny Zaklad Opieki Zdrowotnej (NZOZ)

Krakow, , Poland

Site Status

SPZOZ Uniwersytecki Szpital Kliniczny nr 1

Lodz, , Poland

Site Status

Ostrowieckie Centrum Medyczne

Ostrowiec Świętokrzyski, , Poland

Site Status

SPZOZ Proszowice

Proszowice, , Poland

Site Status

Gabinet Lekarski Zenon Bukowczan

Sucha Beskidzka, , Poland

Site Status

ALL-MED - Specjalistyczna Opieka Medyczna - Medyczny Instytut Badawczy Marek Jutel

Wroclaw, , Poland

Site Status

Centrum Medyczne Melita Medical

Wroclaw, , Poland

Site Status

NZOZ Lekarze Specjalisci

Wroclaw, , Poland

Site Status

Hospital Clinico Universitario de Santiago de Compostela

Santiago de Compostela, A Coruna, Spain

Site Status

Hospital Universitario de Bellvitge

L'Hospitalet de Llobregat, Barcelona, Spain

Site Status

Instituto de Ciencias Medicas

Alicante, , Spain

Site Status

Hospital Clinic de Barcelona

Barcelona, , Spain

Site Status

Hospital Universitari Vall d'Hebron

Barcelona, , Spain

Site Status

Hospital Universitario Doctor Peset

Valencia, , Spain

Site Status

Public Institution: Dnipro Clinical Association of Urgent Medical Care under Dnipro City Council

Dnipro, , Ukraine

Site Status

Public Institution "City Clinical Hospital #4" under Dnipro City Council

Dnipro, , Ukraine

Site Status

Ivano-Frankivsk Central City Clinical Hospital

Ivano-Frankivsk, , Ukraine

Site Status

Public Non-Profit Enterprise: City Clinical Hospital #13 under Kharkiv City Council

Kharkiv, , Ukraine

Site Status

State Organization "National Institute of Phthisiology and Pulmonolgy named after F.G. Yanovsky NAMSU"

Kyiv, , Ukraine

Site Status

State Organization "National Institute of Phthisiology and Pulmonolgy named after F.G. Yanovsky NAMSU"

Kyiv, , Ukraine

Site Status

Public Institution: City Clinical Hospital #6

Zaporizhia, , Ukraine

Site Status

Public Non-Profit Enterprise City Hospital #1 under Zaporizhia City Council

Zaporizhia, , Ukraine

Site Status

Public Enterprise "Hospital #1" under Zhytomyr City Council

Zhytomyr, , Ukraine

Site Status

Birmingham Heartlands Hospital

Birmingham, , United Kingdom

Site Status

Bradford Royal Infirmary

Bradford, , United Kingdom

Site Status

Glasgow Clinical Research Facility, Glasgow Royal Infirmary

Glasgow, , United Kingdom

Site Status

Royal Liverpool University Hospital

Liverpool, , United Kingdom

Site Status

University Hospital Southampton

Southampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Austria Belgium Canada Czechia France Germany Poland Spain Ukraine United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Moss MH, Lugogo NL, Castro M, Hanania NA, Ludwig-Sengpiel A, Saralaya D, Dobek R, Ojanguren I, Vyshnyvetskyy I, Bruey JM, Osterhout R, Tompkins CA, Dittrich K, Raghupathi K, Ortega H; LEDA Investigators. Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma. Chest. 2022 Aug;162(2):297-308. doi: 10.1016/j.chest.2022.02.038. Epub 2022 Mar 3.

Reference Type DERIVED
PMID: 35248549 (View on PubMed)

Ortega H, Fitzgerald M, Raghupathi K, Tompkins CA, Shen J, Dittrich K, Pattwell C, Singh D. A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma. Clin Exp Allergy. 2020 Feb;50(2):189-197. doi: 10.1111/cea.13524. Epub 2019 Nov 26.

Reference Type DERIVED
PMID: 31659803 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GB001-2001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study in Mild Asthmatic Patients
NCT00748306 COMPLETED PHASE2